Dean Slagel serves as Executive at Cara Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Dean Slagel has executed 11 insider transactions totaling $9.9M, demonstrating a bearish approach to their equity position. Their most recent transaction on Jun 29, 2017 involved selling 20,862 shares valued at $554.5K.
Dean Slagel currently holds 1,064,338 shares of Cara Therapeutics, Inc. (CARA), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Dean Slagel has been a net seller of CARA stock. They have purchased $0 and sold $9.9M worth of shares.
Dean Slagel's most recent insider trade was on Jun 29, 2017, when they sold 20,862 shares at $26.58 per share.
Get notified when new Form 4 filings are submitted
| $25.81 |
| Discretionary |
| Jan 5, 2016 | CARA | $531.1K | Sale | 31,224 | $17.01 | Discretionary |
| Jan 5, 2016 | CARA | $531.1K | Sale | 31,224 | $17.01 | Discretionary |
| Dec 31, 2015 | CARA | $217.2K | Sale | 12,776 | $17.00 | Discretionary |
| Dec 31, 2015 | CARA | $217.2K | Sale | 12,776 | $17.00 | Discretionary |
| May 19, 2015 | CARA | $322.7K | Sale | 32,266 | $10.00 | Discretionary |
| May 18, 2015 | CARA | $832.8K | Sale | 82,945 | $10.04 | Discretionary |
| May 15, 2015 | CARA | $736.0K | Sale | 73,600 | $10.00 | Discretionary |
| Feb 5, 2014 | CARA | $0 | Conversion | 84,149 | $N/A | Discretionary |
| Feb 5, 2014 | CARA | $0 | Conversion | 80,000 | $N/A | Discretionary |